Mvix Slows Early Alzheimer’s Decline by Nearly 33% in 40% of Patients
Updated
Updated · The Washington Post · Nov 17
Mvix Slows Early Alzheimer’s Decline by Nearly 33% in 40% of Patients
1 articles · Updated · The Washington Post · Nov 17
Summary
More than 1,500 patients were studied for a year, and Mvix slowed mental decline by nearly a third in early Alzheimer’s patients not already taking other dementia drugs.
About 40% of participants fell into that subgroup; after 12 months, their decline lagged the placebo group by roughly 3.5 months on measures of memory, judgment and daily functioning.
The benefit vanished in the full trial because the other 60%—patients already on standard dementia medicines—showed little to no added improvement, leaving a key question about drug interactions or disease stage.
AriBio says the study still met its prespecified main goal and plans FDA talks on whether the data can support approval without another trial.
If cleared, low-dose Mvix would become the first U.S.-approved pill to slow Alzheimer’s, offering an oral alternative to antibody treatments that require infusions or injections and can cause brain swelling or bleeding.